Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis To Increase Fluzone Supply As Wyeth’s FluShield Exits Market

Executive Summary

Aventis-Pasteur is in discussions with FDA and the Centers for Disease Control & Prevention on ways to increase the supply of its influenza vaccine Fluzone following Wyeth's decision to discontinue FluShield
Advertisement

Related Content

FDA To Determine Flu Vaccine Suppliers For 2005-2006 Season In January
Chiron Vaccines Get Shot In The Arm With PowderJect Needleless Technology
Wyeth FluMist Draft Label Will Be Reviewed By CDC Cmte. To Speed Coverage
Flu vaccine funding
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
Vaccine Manufacturing Data Could Be Shared To Prevent Shortages – Aventis
FDA Concerned By Shrinking Vaccine Supplier Pool, CBER's Zoon Says
King Fluogen Discontinued; Flu Vaccine Would Have Been Unavailable In 2000
King Fluogen Discontinued; Flu Vaccine Would Have Been Unavailable In 2000
Advertisement
UsernamePublicRestriction

Register

PS040830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel